GSK Romania finalizes USD 7 million investment in Brasov plant

Newsroom 15/11/2011 | 13:37

GlaxoSmithKline (GSK) has finalized a USD 7 million investment in two production lines at its Brasov plant in Romania. The investment, which spread over a three-year period, was made in the lines manufacturing products in the company’s global portfolio: the antidepressant Seroxat and the HIV treatment Retrovir. Up until three years ago, the plant was manufacturing only local pharmaceutical brands pertaining to the Europharm portfolio and intended to reach the local market exclusively.

With this investment the Brasov plant is now exporting drugs in over 80 countries worldwide, compared to 50 countries reached at the end of 2010. The largest export markets for the Brasov plant are France and Italy, which take up around 24 percent of total exports. The GSK plant in Brasov started exporting in 2008, and today around 60 percent of its output is sent overseas.

“For the future we plan to transfer the production of global GSK brands to the Brasov plant and at the same time increase the number of countries we reach with products manufactured in Romania,” said Pascal Prigent, general manager of GSK Romania.

BR Magazine | Latest Issue

Download PDF or read online: November 2022 Issue | Business Review Magazine

The November 2022 issue of Business Review Magazine is now available in digital format, featuring the main cover story titled “Samsung Remains Top Consumer Tech Provider on Romanian Market.” Read
Newsroom | 29/11/2022 | 10:17

    You will receive a download link for the latest issue of Business Review Magazine in PDF format, based on the completion of the form below.

    I agree with the Privacy policy of
    I agree with the storage and handling of my data by
    Advertisement Advertisement
    Close ×

    We use cookies for keeping our website reliable and secure, personalising content and ads, providing social media features and to analyse how our website is used.

    Accept & continue